ArticleCirculation2014
Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity.
Article in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02428374 (Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study), which is not on this map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas.Circulation research · 2020Pooled it
- Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis.Journal of the American Heart Association · 2014Trial
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- Neuroimmune circuits in the plaque and bone marrow regulate atherosclerosis.Cardiovascular research · 2025Review
- Molecular mechanisms and therapeutic progress in atherosclerosis: bridging immune inflammation and precision medicine.Frontiers in immunology · 2025Review
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- Impact of Methylated Cyclodextrin KLEPTOSEInternational journal of molecular sciences · 2024Article
- Article
- T-Cell/B-Cell Interactions in Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- B cells and atherosclerosis: A HIV perspective.Journal of cellular physiology · 2024Review
- Immunometabolism in atherosclerotic disorders.Nature cardiovascular research · 2024Review
- Discovering Inflammation in Atherosclerosis: Insights from Pathogenic Pathways to Clinical Practice.International journal of molecular sciences · 2024Review
- Immunological perspectives on atherosclerotic plaque formation and progression.Frontiers in immunology · 2024Review
- The role of immune cells in different stages of atherosclerosis.International journal of medical sciences · 2024Review
- Atherosclerosis antigens as targets for immunotherapy.Nature cardiovascular research · 2023Review
- Single-cell profiling reveals age-associated immunity in atherosclerosis.Cardiovascular research · 2023Article
- Article
- B-1 cells in immunotoxicology: Mechanisms underlying their response to chemicals and particles.Frontiers in toxicology · 2023Review
- Molecular and cellular mechanisms of inflammation in atherosclerosis.Frontiers in cardiovascular medicine · 2023Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 4 countries.
Funding
Abstract
backgroundAtherosclerotic lesions grow via the accumulation of leukocytes and oxidized lipoproteins in the vessel wall. Leukocytes can attenuate or augment atherosclerosis through the release of cytokines, chemokines, and other mediators. Deciphering how leukocytes develop, oppose, and complement each other's function and shape the course of disease can illuminate our understanding of atherosclerosis. Innate response activator (IRA) B cells are a recently described population of granulocyte macrophage colony-stimulating factor-secreting cells of hitherto unknown function in atherosclerosis. METHODS AND
resultsHere, we show that IRA B cells arise during atherosclerosis in mice and humans. In response to a high-cholesterol diet, IRA B cell numbers increase preferentially in secondary lymphoid organs via Myd88-dependent signaling. Mixed chimeric mice lacking B cell-derived granulocyte macrophage colony-stimulating factor develop smaller lesions with fewer macrophages and effector T cells. Mechanistically, IRA B cells promote the expansion of classic dendritic cells, which then generate interferon γ-producing T helper-1 cells. This IRA B cell-dependent T helper-1 skewing manifests in an IgG1-to-IgG2c isotype switch in the immunoglobulin response against oxidized lipoproteins.
conclusionsGranulocyte macrophage colony-stimulating factor-producing IRA B cells alter adaptive immune processes and shift the leukocyte response toward a T helper-1-associated milieu that aggravates atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.